MAKING CANCER TREATMENTS
SAFER AND MORE EFFECTIVE

At Corventum we believe that making existing cancer therapies safer and more effective benefits all stakeholders: patients, payers, and providers. In the current era in oncology, when ever more complex and expensive biological molecules are being trialed in ever smaller patient cohorts, we believe we can be different and make a positive impact on as many patients as possible, as soon as possible. We will begin by developing new therapies that protect the heart from the toxic effects of cancer treatment, keeping the heart safe so that patients can continue first-line cancer treatment without interruption.

SHIELDING THE HEART
DURING CANCER TREATMENT

Some of the most effective treatments for cancer cause life-threatening toxicities that affect the heart. These toxicities can lead to heart failure, a devastating condition that affects quality of life and results in high mortality. The development of heart toxicity also causes first-line cancer treatments to be withheld, preventing patients from achieving the best cancer outcomes. Our first program, CVT-130, is a small molecule that we will be advancing into the clinic in 2025.